Li Lab: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
(4 intermediate revisions by the same user not shown)
Line 6: Line 6:
<div style="float:left;margin-left:0.3em;margin-right:0.7em">
<div style="float:left;margin-left:0.3em;margin-right:0.7em">


== '''Computational Epigenomics and Transcriptomics Lab (PI: Wei Li)''' ==  
== '''Computational Cancer Epigenomics and Transcriptomics (PI: Wei Li)''' ==  


[http://www.bcm.edu/cancercenter/ Dan L. Duncan Cancer Center], [http://www.bcm.edu/mcb/index.html Department of Molecular and Cellular Biology], [http://www.bcm.edu/ Baylor College of Medicine]
[http://www.bcm.edu/cancercenter/ Dan L. Duncan Cancer Center], [http://www.bcm.edu/mcb/index.html Department of Molecular and Cellular Biology], [http://www.bcm.edu/ Baylor College of Medicine]
Line 15: Line 15:


==Recent News==
==Recent News==
. 12/2013:  Zheng Xia received Keck fellowship in Computational Cancer Biology.
. 12/2014: We will receive a 3-year '''CPRIT R01''' grant to study 3`-UTR alterations in human cancers. Also Two Collaboration CPRIT grants will funded: Chromatin Regulation with Lee lab, aging with Tyler lab in MD Anderson
 
. 12/2014:  Zheng Xia awarded '''Keck fellowship''' in Computational Cancer Biology.
 
. 11/2013:  Zheng's DaPars 3'UTR Pan Cancer analysis paper is published in '''Nature Communications''';


. 09/2014:  Liguo's ChIP-exo methodology paper (MACE) is accepted to '''Nucleic Acids Research'''.  MACE is recommended by Active Motif as the software solution for the company's new [https://www.activemotif.com/catalog/1050/chip-exo ChIP-exo kit and service].
. 09/2014:  Liguo's ChIP-exo methodology paper (MACE) is accepted to '''Nucleic Acids Research'''.  MACE is recommended by Active Motif as the software solution for the company's new [https://www.activemotif.com/catalog/1050/chip-exo ChIP-exo kit and service].
Line 21: Line 25:
. 09/2013: Deqiang will start his tenure-track assistant professor position. Job well done.   
. 09/2013: Deqiang will start his tenure-track assistant professor position. Job well done.   


. 09/2013:  Zheng's prostate cancer RNA-seq paper with Dr. Balk at Harvard is accepted to '''Molecular Cancer Research '''. Yuanxin's work on H3K79 Methylation with Dr. Shi is accepted to '''Cell'''.
. 09/2013:  Zheng's prostate cancer RNA-seq paper with Dr. Balk at Harvard is accepted to '''Molecular Cancer Research '''.  


. 08/2013:  Zheng's DaPars 3'UTR Pan Cancer analysis paper is accepted in principle to '''Nature Communications''';
. 09/2013:  Yuanxin's work on H3K79 Methylation with Dr. Shi is accepted to '''Cell'''.


. 08/2013:  '''Three Collaboration CPRIT grants''' are funded: DNA methylation with Goodell lab, 3'UTR with Wagner lab and ZM11 with Shi lab.
. 08/2013:  '''Three Collaboration CPRIT grants''' are funded: DNA methylation with Goodell lab, 3'UTR with Wagner lab and ZM11 with Shi lab.
Line 29: Line 33:
. 08/2014:  Kaifu's "super promoter" paper is under review in '''Nature Genetics'''.  
. 08/2014:  Kaifu's "super promoter" paper is under review in '''Nature Genetics'''.  


. 06/2014:  Deqiang's Dnmt3a/3b double KO paper (with the Goodell Lab) is accepted to '''Cell Stem Cell '''.  
. 06/2014:  Deqiang's Dnmt3a/3b double KO paper (w/ Goodell Lab) is accepted to '''Cell Stem Cell '''.  


. 06/2014:  Zheng's alternative splicing paper (with the Cooper Lab) is accepted to '''Molecular Cell '''.  
. 06/2014:  Zheng's alternative splicing paper (w/ Cooper Lab) is accepted to '''Molecular Cell '''.  


. 02/2014:  Deqiang and Hyun Jung's HSC LncRNA paper (with the Goodell Lab) is in revision in '''Cell Stem Cell'''.  
. 02/2014:  Deqiang and Hyun Jung's HSC LncRNA paper (w/ Goodell Lab) is in revision in '''Cell Stem Cell'''.  


. 02/2014:  Zheng's collaborative work on alternative splicing in heart development is accepted to '''Nature Communications'''.  
. 02/2014:  Zheng's collaborative work on alternative splicing in heart development is accepted to '''Nature Communications'''.  

Revision as of 09:43, 23 December 2014

Home        People        Publications        Collaborations        Software        Positions        Contact       


Recent News

. 12/2014: We will receive a 3-year CPRIT R01 grant to study 3`-UTR alterations in human cancers. Also Two Collaboration CPRIT grants will funded: Chromatin Regulation with Lee lab, aging with Tyler lab in MD Anderson

. 12/2014: Zheng Xia awarded Keck fellowship in Computational Cancer Biology.

. 11/2013: Zheng's DaPars 3'UTR Pan Cancer analysis paper is published in Nature Communications;

. 09/2014: Liguo's ChIP-exo methodology paper (MACE) is accepted to Nucleic Acids Research. MACE is recommended by Active Motif as the software solution for the company's new ChIP-exo kit and service.

. 09/2013: Deqiang will start his tenure-track assistant professor position. Job well done.

. 09/2013: Zheng's prostate cancer RNA-seq paper with Dr. Balk at Harvard is accepted to Molecular Cancer Research .

. 09/2013: Yuanxin's work on H3K79 Methylation with Dr. Shi is accepted to Cell.

. 08/2013: Three Collaboration CPRIT grants are funded: DNA methylation with Goodell lab, 3'UTR with Wagner lab and ZM11 with Shi lab.

. 08/2014: Kaifu's "super promoter" paper is under review in Nature Genetics.

. 06/2014: Deqiang's Dnmt3a/3b double KO paper (w/ Goodell Lab) is accepted to Cell Stem Cell .

. 06/2014: Zheng's alternative splicing paper (w/ Cooper Lab) is accepted to Molecular Cell .

. 02/2014: Deqiang and Hyun Jung's HSC LncRNA paper (w/ Goodell Lab) is in revision in Cell Stem Cell.

. 02/2014: Zheng's collaborative work on alternative splicing in heart development is accepted to Nature Communications.

. 02/2014: Zheng's brain tumor 3'UTR regulator paper is accepted to Nature. This paper was initially rejected after review twice. We appealed twice with success and finally made it in the 3rd submission.

. 02/2014: Welcome our new postdoc Jianzhong Su and graduate student Xueqiu Lin.

. 02/2014: Deqiang's mouse HSC Aging Epigenomics paper is accepted in principle to Cell Stem Cell.

. 01/2014: Deqiang's Methodology paper for the detection of differential DNA Methylation (MOABS) is accepted to Genome Biology.

. 01/2014: Our collaborative work on Breast Cancer Epigenetics is accepted to Science Translational Medicine.

. 01/2014: Yuanxin and Zheng's ZM11 paper with Xiaobing Shi lab in MD Anderson is accepted to Nature. This work links transcription elongation to tumor suppression.

. 12/2013: Kaifu's aging nucleosome paper is accepted to Genes & Development

. 12/2013: We received a 5-year NIH/NHGRI R01 grant (scored at 6 percentile in its first submission) to study DNA Methylation

. 11/2013: Wei will serve on the Editorial Board of Molecular Endocrinology

. 09/2013: Deqiang's DNA methylation Canyon paper is accepted to Nature Genetics.

. 09/2013: Xueqiu's bisulfite sequencing quality control paper (BSeQC) is accepted to Bioinformatics.

. 08/2013: Kadir's p53 paper is accepted to Nucleic Acids Research

. 01/2013: BCM News and Epigenie Headline about our recent work on nucleosome dynamics.


News Archive




Our lab is focused on the design and application of bioinformatics algorithms to elucidate global epigenetic mechanisms and transcription dynamics in normal development and diseases such as cancer. Since establishing the lab in early 2008, we have published more than 66 peer-reviewed papers in high profile journals, such as Nature, Cell, Nature Genetics, Cell Stem Cell, Molecular Cell, Nature Communications, Genome Research, Genome Biology, PNAS, Genes and Development, Nucleic Acids Research, Cancer Research, and Bioinformatics.

We have developed a number of widely used algorithms to analyze next generation sequencing data from ChIP-seq (MACS, MACE, DyChIPS), DNA methylation Bisulfite-seq (BSMAP/RRBSMAP, BSeQC, MOABS), nucleosome positioning MNase-seq (DANPOS), and RNA-seq (CPAT, RSeQC, DaPars). These algorithms have been broadly adopted by thousands of academic users. For example, the MACS algorithm has gathered >1600 citations since 2008.

In collaboration with experimental biologists, we used these algorithms to gain novel biological insights from various biological processes and disease models.

  • Chromatin Factors: ER in breast cancer, AR in prostate cancer, FoxA1 pioneer factor, Atoh1 in neuron development, NSD2 in oncogenic programming, SIRT7 in cancer transformation, ZM11 in transcription elongation, and p53 in ES differentiation..
  • DNA Methylation: DNA methylation Canyon, Epigenetic changes in HSC aging, Dnmt3a in HSC differentiation and cancer transformation.
  • Nucleosome Organization: Fragile nucleosome in stress-response, Promoter nucleosome with Tup1, Nucleosome dynamics in ES differentiation, and Global nucleosome loss in yeast aging.
  • Transcriptome: chimeric RNA in prostate cancer, Long non-coding RNA in HSC, 3’UTR deletion in cancer and its master regulator CFIm25. .


Lab Intranet openwetware


<html> <script type="text/javascript">

 var _gaq = _gaq || [];
 _gaq.push(['_setAccount', 'UA-5924762-2']);
 _gaq.push(['_trackPageview']);
 (function() {
   var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
   ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
   var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
 })();

</script> </html>